We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+23.8%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$239M
AUM Growth
+$38.5M
Cap. Flow
+$5.11M
Cap. Flow %
2.14%
Top 10 Hldgs %
60.96%
Holding
53
New
9
Increased
15
Reduced
7
Closed
12

Top Buys

Rank Stock Value
1
ARDX icon
Ardelyx
ARDX
+$4.64M
2
CORI
Corium International, Inc.
CORI
+$3.29M
3
XLRN
Acceleron Pharma
XLRN
+$2.9M
4
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
+$2.83M
5
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$2.55M

Top Sells

Rank Stock Value
1
TVRD
Tvardi Therapeutics
TVRD
+$7.08M
2
OCUL icon
Ocular Therapeutix
OCUL
+$5.1M
3
SAGE
Sage Therapeutics
SAGE
+$3.2M
4
GNMX
Aevi Genomic Medicine Inc
GNMX
+$1.99M
5
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$1.96M

Sector Composition

Rank Sector Weight
1 Healthcare 98.92%
2 Miscellaneous 1.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GNMX
51
DELISTED
Aevi Genomic Medicine Inc
GNMX
– –
-1,070,000
Closed -$1.99M
1 2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2017 Portfolio in Review

As of Q2 2017, Opaleye Management held 53 positions worth $239M, up 19% from $201M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Opaleye Management's Q2 2017 filing shows 9 new, 15 increased, 7 reduced and 12 closed positions. Its largest new stake was Ardelyx: 546,500 shares worth $2.79M. The largest sale was Tvardi Therapeutics, an estimated $7.08M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

  • Opaleye Management's largest Q2 2017 buy was Ardelyx: 546,500 shares worth $2.79M.
  • Opaleye Management added most to Corium International, Inc. in Q2 2017, an estimated $3.29M increase.
  • Opaleye Management's biggest Q2 2017 reduction was PDS Biotechnology, cutting an estimated $1.48M.
  • Opaleye Management fully exited Tvardi Therapeutics in Q2 2017, selling an estimated $7.08M.
  • Opaleye Management's ten largest holdings make up 61% of its $239M portfolio in Q2 2017.
  • Opaleye Management opened 9 new positions and closed 12 in Q2 2017.
  • Opaleye Management's portfolio value rose 19% quarter-over-quarter to $239M.

Based on Opaleye Management's 13F filing for Q2 2017, filed 14 Aug 2017.